Frega G.; Palloni A.; Di Pasquale G.; Saccoccio G.; Rizzo A.; Poluzzi E.; Iannone P.; Brandi G., Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements, «FRONTIERS IN PHARMACOLOGY», 2020, 11, Article number: 559996 , pp. 1 - 6 [Scientific article]Open Access
Raschi E.; Fusaroli M.; Diemberger I.; Poluzzi E., Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance, «DRUG SAFETY», 2020, 43, pp. 1191 - 1194 [Scientific article]
Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F., Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, «TARGETED ONCOLOGY», 2020, 15, pp. 449 - 466 [Scientific article]Open Access
Gatti M.; Poluzzi E.; De Ponti F.; Raschi E., Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, «DRUG SAFETY», 2020, 43, pp. 1277 - 1285 [Scientific article]Open Access
Iommi M.; Rosa S.; Fusaroli M.; Rucci P.; Fantini M.P.; Poluzzi E., Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions, «PLOS ONE», 2020, 15, Article number: e0240899 , pp. 1 - 13 [Scientific article]Open Access
Antonazzo I.C.; Poluzzi E.; Forcesi E.; Salvo F.; Pariente A.; Marchesini G.; De Ponti F.; Raschi E., Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system, «ACTA DIABETOLOGICA», 2020, 57, pp. 71 - 80 [Scientific article]
Lunghi C.; Antonazzo I.C.; Burato S.; Raschi E.; Zoffoli V.; Forcesi E.; Sangiorgi E.; Menchetti M.; Roberge P.; Poluzzi E., Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study, «NEUROPSYCHIATRIC DISEASE AND TREATMENT», 2020, 16, pp. 1157 - 1170 [Scientific article]Open Access
Raschi E.; Poluzzi E.; De Ponti F., Reduced neuropsychiatric events as “beneficial reactions” to drugs: Seek associations with caution, «BRAIN BEHAVIOR AND IMMUNITY», 2020, 84, pp. 275 - 276 [Comment or similar]
Raschi E, Salvo F, La Placa M, Poluzzi E, De Ponti F, Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction., «JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY», 2020, 34, pp. 430e - 431e [Scientific article]
Gatti M.; Ippoliti I.; Poluzzi E.; Antonazzo I.C.; Moro P.A.; Moretti U.; Menniti-Ippolito F.; Mazzanti G.; De Ponti F.; Raschi E., Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements, «CLINICAL NUTRITION», 2020, 39, pp. 3854 - 3855 [Comment or similar]
Swart, Floor; Bianchi, Giampaolo; Lenzi, Jacopo; Iommi, Marica; Maestri, Lorenzo; Raschi, Emanuel; Zoli, Marco; Ponti, Fabrizio De; Poluzzi, Elisabetta, Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database, «AGING», 2020, 12, pp. 19711 - 19739 [Scientific article]Open Access
Antonazzo I.C.; Poluzzi E.; Forcesi E.; Salvo F.; Pariente A.; Marchesini G.; De Ponti F.; Raschi E., Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution, «ACTA DIABETOLOGICA», 2020, 57, pp. 115 - 116 [Comment or similar]
Gatti M.; Raschi E.; Poluzzi E.; Martignani C.; Salvagni S.; Ardizzoni A.; Diemberger I., The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia, «CURRENT HEART FAILURE REPORTS», 2020, 17, pp. 365 - 383 [Scientific article]Open Access
Kaguelidou F.; Holstiege J.; Schink T.; Bezemer I.; Poluzzi E.; Mazzaglia G.; Pedersen L.; Sturkenboom M.; Trifiro G., 'Use of antipsychotics in children and adolescents: A picture from the ARITMO population-based European cohort study', «EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES», 2020, 29, Article number: e117 , pp. 1 - 9 [Scientific article]Open Access
Raschi E.; Poluzzi E.; Marchesini G.; De Ponti F., Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?, «EXPERT OPINION ON PHARMACOTHERAPY», 2019, 20, pp. 1087 - 1090 [Scientific article]Open Access
